Peptide Research Evidence Checklist for Readers
Use a printable peptide research checklist to verify sources, endpoints, uncertainty, harms and approval claims. Includes a worked trial example.
Key takeaways
- Check one specific claim rather than a whole molecule.
- Record missing information without assumptions.
- A checklist is not a numerical medical evidence grade.
In this article
Before believing a peptide claim, check the exact source, studied population, comparator, outcome, uncertainty, harms and current product status. This checklist helps you describe what the evidence supports. It is not a diagnostic tool, treatment recommendation or validated numerical grading system.
Use it for one specific claim at a time. “Changed a laboratory signal” and “improved recovery in patients” need different evidence. Start with our evidence center if the distinction is unfamiliar.
Printable evidence checklist
Download the plain-text checklist to save, fill in or print from a text editor. Record “not reported” when a source does not provide an answer; do not fill gaps with assumptions.
| Check | Record this | Why it matters |
|---|---|---|
| Exact claim | Proposed effect and who it concerns | Prevents a mechanism claim becoming a treatment claim |
| Original source | Title, DOI/PMID/NCT number and access date | Makes verification repeatable1 |
| Current version | Correction, concern or retraction notice, if any | An old PDF may differ from the current record2 |
| Research level | Cells, animals, healthy volunteers or patients | Different models answer different questions |
| Exact intervention | Molecule, formulation and route | Parent peptides, fragments and commercial products can differ |
| Study design | Randomization, masking and comparator | Helps assess competing explanations |
| Sample and follow-up | Randomized number, analyzed number and duration | Short or small studies cannot settle all safety questions |
| Planned endpoint | Primary outcome and relevant secondary outcomes | Limits selective emphasis |
| Effect and uncertainty | Between-group estimate, units and confidence interval | A P value alone does not show clinical usefulness3 |
| Missing data and harms | Withdrawals, exclusions and adverse-event collection | Benefits and risks need the same scrutiny |
| Funding and replication | Sponsor, conflicts and independent reports | Transparency supports assessment, not automatic acceptance or rejection |
| Regulatory scope | Named product, indication, jurisdiction and date | Registration and publication do not establish approval |
Keep identifiers separate
A PMID identifies a PubMed citation, a DOI identifies a scholarly object, and an NCT number identifies a ClinicalTrials.gov record. None is a standalone certificate of study quality. PubMed can include different publication formats; check the actual record and publisher.1
How to turn the checklist into an honest conclusion
If the evidence is preclinical
Use wording such as “the compound changed this outcome in the studied animal model.” Do not remove the species or assign a patient benefit. Our human versus preclinical research guide explains translation limits.
If a human report is uncontrolled or exploratory
State the population, sample, measured outcome and absence of an adequate control where applicable. Improvement after exposure cannot isolate the compound from background care, natural recovery or selection effects.
If there is a randomized trial
Check how it was conducted, what was measured and how precise the estimate is. Randomization strengthens a causal comparison when maintained appropriately; it does not eliminate every risk of bias or establish applicability to different people, products or endpoints. The results-table guide covers analysis assumptions and denominators.
If important details are missing
Write “the claim cannot be assessed reliably from this source.” Missing information does not establish that a result is false, but it limits confidence. Avoid adding ticks into a supposed score: several superficial strengths cannot compensate for a serious mismatch between the claim and endpoint. Evidence certainty considers design, bias, precision, consistency and applicability together.3
Worked example: avoid widening a real trial result
STEP 1 randomized 1,961 adults with overweight or obesity without diabetes to semaglutide or placebo with lifestyle intervention for 68 weeks. Mean weight change was −14.9% versus −2.4%; gastrointestinal events led to treatment discontinuation in 4.5% versus 0.8%. Novo Nordisk funded the trial.4
A faithful summary retains the specific population, product, comparator, duration and harms. “Every peptide causes this amount of weight loss” would widen one trial’s finding to unrelated molecules and individuals. The trial also does not verify an unrelated seller’s vial.
Our semaglutide profile links current product-specific U.S. prescribing information checked 10 October 2026. Keep approval claims separate from trial interpretation.
Save a claim-sized summary
Complete this sentence:
In [population/model], [exact intervention] was compared with [comparator] over [duration], measuring [endpoint]. The result was [estimate and uncertainty], with [important harms/limitations]. It does not establish [specific unsupported extension].
Then save the original source and access date. Recheck important sources before repeating a claim, especially if publication or regulatory status may have changed. For source-status checking, use our peer-review verification guide and correction/retraction guide.
References
- NLM: PubMed User Guide. Citation identifiers, publication types and full-text links.
- ICMJE: corrections and version control.
- Cochrane Handbook, Chapter 14: evidence certainty and findings. Background for certainty concepts; this reader worksheet is not a formal GRADE assessment.
- Wilding JPH et al. STEP 1, 2021. PMID 33567185; DOI 10.1056/NEJMoa2032183; NCT03548935.
Sources checked 10 October 2026. Educational checklist; no experimental dosing or individual medical advice.
